Last reviewed · How we verify
Allogeneic peripheral blood stem cell transplant
Approved treatments
- Neulasta · Amgen
Colony-stimulating factor binding hematopoietic cell surface receptors to stimulate proliferation and differentiation. - FULPHILA · MYLAN GMBH
- Neulasta · Amgen
Neulasta stimulates the production of white blood cells by binding to their receptors. - Trecondi · Medexus
- Neulasta · Columbia University
Clinical guidelines
- FDA label — not applicable
NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Allogeneic peripheral blood stem cell transplant patent landscape — cliff calendar, originator estates, attackable patents
- Allogeneic peripheral blood stem cell transplant treatment landscape brief
- Allogeneic peripheral blood stem cell transplant treatment updates RSS
Frequently asked questions about Allogeneic peripheral blood stem cell transplant
What drugs treat Allogeneic peripheral blood stem cell transplant?
Tracked treatments include Neulasta, FULPHILA, Trecondi.
What is the treatment for Allogeneic peripheral blood stem cell transplant?
Standard treatment for Allogeneic peripheral blood stem cell transplant includes Neulasta, FULPHILA, Trecondi. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Allogeneic peripheral blood stem cell transplant?
FDA label publishes guidelines for Allogeneic peripheral blood stem cell transplant. 1 guideline references tracked.
Related
- Treatment landscape: Allogeneic peripheral blood stem cell transplant patent cliff · Allogeneic peripheral blood stem cell transplant CI report
- Treatment: Neulasta · Amgen
- Treatment: FULPHILA · MYLAN GMBH
- Treatment: Neulasta · Amgen
- Treatment: Trecondi · Medexus
- Treatment: Neulasta · Columbia University
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing